Skip to main content

Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.

Publication ,  Journal Article
D'Souza, A; Brazauskas, R; Dispenzieri, A; Panepinto, J; Flynn, KE
Published in: Blood Cancer J
February 1, 2021

We conducted a prospective cohort study in newly diagnosed systemic light chain (AL) amyloidosis patients (N = 59) to study patient-reported outcomes (PROs) through the first year. The median age was 68 years with 42% female, 8% Black, and 78% lambda subtype. Organ involvement was cardiac in 66%, renal in 58%, with 25% having 3 or greater organs involved. Between baseline and 3 months, all PROMIS®-29 domain scores worsened by 0.4-4.1 points except anxiety which improved by 2.1 points. By 1 year, scores improved compared to the greatest decline at 3 months, most statistically significant for global physical health, physical function, and fatigue. On stage-adjusted survival analysis, in addition to baseline global physical and mental health, domains measuring physical function, fatigue, anxiety, depression, and social roles were associated with 1-year survival. At 1 year, PROMIS measures were associated with NT-proBNP changes and hematologic response. Among patients with an NT-proBNP response, the improvement was seen in physical function, social roles, global mental health, and anxiety. Among patients with an NT-proBNP progression, worsening was seen with anxiety, depression, sleep, and global mental health. Measuring and tracking PROs in patients with AL amyloidosis is important and these important outcomes can be used as correlative endpoints in clinical care/research.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Cancer J

DOI

EISSN

2044-5385

Publication Date

February 1, 2021

Volume

11

Issue

2

Start / End Page

29

Location

United States

Related Subject Headings

  • Prospective Studies
  • Prognosis
  • Peptide Fragments
  • Patient Reported Outcome Measures
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Mental Health
  • Male
  • Immunoglobulin Light-chain Amyloidosis
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
D’Souza, A., Brazauskas, R., Dispenzieri, A., Panepinto, J., & Flynn, K. E. (2021). Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. Blood Cancer J, 11(2), 29. https://doi.org/10.1038/s41408-021-00412-8
D’Souza, Anita, Ruta Brazauskas, Angela Dispenzieri, Julie Panepinto, and Kathryn E. Flynn. “Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.Blood Cancer J 11, no. 2 (February 1, 2021): 29. https://doi.org/10.1038/s41408-021-00412-8.
D’Souza A, Brazauskas R, Dispenzieri A, Panepinto J, Flynn KE. Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. Blood Cancer J. 2021 Feb 1;11(2):29.
D’Souza, Anita, et al. “Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.Blood Cancer J, vol. 11, no. 2, Feb. 2021, p. 29. Pubmed, doi:10.1038/s41408-021-00412-8.
D’Souza A, Brazauskas R, Dispenzieri A, Panepinto J, Flynn KE. Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change. Blood Cancer J. 2021 Feb 1;11(2):29.

Published In

Blood Cancer J

DOI

EISSN

2044-5385

Publication Date

February 1, 2021

Volume

11

Issue

2

Start / End Page

29

Location

United States

Related Subject Headings

  • Prospective Studies
  • Prognosis
  • Peptide Fragments
  • Patient Reported Outcome Measures
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Mental Health
  • Male
  • Immunoglobulin Light-chain Amyloidosis
  • Humans